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Dacarbazine-Mediated Upregulation of NKG2D
Ligands on Tumor Cells Activates NK and CD8
T Cells and Restrains Melanoma Growth
Alice Hervieu1,2,3,4, Ce´dric Re´be´1,2,5, Fre´de´rique Ve´gran1,2, Fanny Chalmin1,2, Me´lanie Bruchard1,2,
Pierre Vabres4, Lionel Apetoh1,2,5, Franc¸ois Ghiringhelli1,2,3,5,6 and Gre´goire Mignot1,2,6
Dacarbazine (DTIC) is a cytotoxic drug widely used for melanoma treatment. However, the putative contribution
of anticancer immune responses in the efficacy of DTIC has not been evaluated. By testing how DTIC affects
host immune responses to cancer in a mouse model of melanoma, we unexpectedly found that both natural
killer (NK) and CD8þ T cells were indispensable for DTIC therapeutic effect. Although DTIC did not directly
affect immune cells, it triggered the upregulation of NKG2D ligands on tumor cells, leading to NK cell activation
and IFNg secretion in mice and humans. NK cell–derived IFNg subsequently favored upregulation of major
histocompatibility complex class I molecules on tumor cells, rendering them sensitive to cytotoxic CD8þ T cells.
Accordingly, DTIC markedly enhanced cytotoxic T lymphocyte antigen 4 inhibition efficacy in vivo in an
NK-dependent manner. These results underscore the immunogenic properties of DTIC and provide a rationale
to combine DTIC with immunotherapeutic agents that relieve immunosuppression in vivo.
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INTRODUCTION
Beyond their cytotoxicity on tumor cells, some anticancer
agents promote the activation of the host immune system,
which can make a decisive contribution to therapeutic success
(Apetoh et al., 2008; Zitvogel et al., 2008). Drugs such as
cyclosphosphamide and 5-fluorouracil were indeed, respec-
tively, shown to selectively deplete regulatory T cells (Tregs)
(Ghiringhelli et al., 2004) and myeloid-derived suppressor
cells (MDSCs) (Vincent et al., 2010; Apetoh et al., 2011)
in vivo, resulting in enhanced antitumor responses. In addition,
anthracyclines, oxaliplatin, and radiotherapy induce immuno-
genic cell death, leading to the activation of T cell–based
anticancer immune responses (Apetoh et al., 2007; Obeid et al.,
2007; Ghiringhelli et al., 2009). Platinum derivates were also
shown to stimulate the expression of ligands for NKG2D, an
natural killer (NK) cell–activating receptor, which determines
the innate immune response against leukemic tumors (Gasser
et al., 2005). NKG2D recognition by NK cells may be a
preponderant mechanism in some cancers, including melano-
ma (Pende et al., 2001), and regulation of NKG2D ligand
expression by tumor cells affects NK cell cytotoxicity (Pietra
et al., 2012). Many different NKG2D ligands have been
described to be differentially expressed between models,
namely Rae-1, Mult-1, and H-60 in mice, and MICA, MICB
and ULBPs in human cells. These ligands are activators of NK
cell functions when membrane bound (Sutherland et al., 2006;
Champsaur and Lanier, 2010), but may also inhibit immunity in
their soluble form (Salih et al., 2008; Paschen et al., 2009).
Dacarbazine (DTIC) is an alkylating agent approved to
treat metastatic melanoma in humans. This has been admini-
stered as a first-line treatment for metastatic melanoma since
the 1970s (Gerner et al., 1975) and is still used as such when
mutant BRaf-targeting therapy is not applicable. However,
response rates to this treatment remain poor (Lui et al., 2007).
Although the direct cytotoxic activity of DTIC has been
known for long, little information is currently available about
DTIC immunomodulatory effects. To address how DTIC affects
anticancer immune responses, we evaluated the contribution
of innate and adaptive immune cells in the anticancer effects
of DTIC in a mouse melanoma model. We found that NK and
CD8þ T cells were both required for DTIC antitumor activity.
DTIC induced upregulation of NKG2D ligands on B16
melanoma cells and human melanoma cells, leading to NK
cell activation. Activated NK cells produced IFNg, which
enhanced major histocompatibility complex I (MHC-I) tumor
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cell expression, resulting in the activation of antitumor-
specific CD8þ T cells in vitro and in vivo. Furthermore, a
combination of DTIC with cytotoxic T lymphocyte antigen
4 (CTLA4) blockade also has an NK-dependent antitumor
effect. These results underscore the immunogenic properties
of DTIC that rely on its ability to induce NKG2D ligand
expression on tumor cells.
RESULTS
DTIC exerts an antitumor effect in a CD8-, IFNc-, and
NK-dependent manner
We first treated wild-type or nude mice bearing a subcuta-
neous B16F10 melanoma tumor with DTIC. This treatment
delayed tumor growth in wild-type mice but had no effect on
tumor progression in nude mice, suggesting that the DTIC
antitumor effect depends on T cells (Figure 1a).
To further delineate the contribution of the host immune
response to the anticancer effect of DTIC, we treated tumor-
bearing mice with DTIC along with isotype or depleting
anti-CD8, CD4, IFNg, or NK1.1 antibodies to eliminate, respec-
tively, CD8þ T cells (Figure 1b), CD4þ T cells (Figure 1c),
IFNg (Figure 1d), or NK cells (Figure 1e). Although CD4þ
T cells were dispensable for DTIC therapeutic efficacy, we
found that the DTIC antitumor effect relied on CD8þ T cells,
IFNg, and NK cells. Interestingly, in NK- and IFNg-depleted
mice, the DTIC effect was totally abrogated, whereas in
CD8þ T cell–depleted mice DTIC only exerted an early and
transient effect on tumor progression, suggesting that NK cells
and IFNg, which act as early effectors against tumor progres-
sion, might subsequently trigger CD8þ T-cell activation. To
further assess the immune-based effect of DTIC, we inocu-
lated mice with 10 less B16F10 cells than usual and treated
them according to the standard protocol. We observed that in
mice in which the low-dose tumor was implanted, the DTIC
was more effective, suggesting a nontumor-based phenom-
enon (Figure 1f).
Taken together, these data underscore the contribution of
CD8þ T cells, IFNg, and NK cells in the anticancer activity of
DTIC.
DTIC does not directly affect immune effectors
Chemotherapy could harness the host immune system by
eliminating immunosuppressive cells such as Tregs and
MDSCs (Ghiringhelli et al., 2004; Suzuki et al., 2005; Vincent
et al., 2010), by inducing dendritic cell (DC) maturation
(Tanaka et al., 2009) or by eliciting ‘‘immunogenic cell death’’
of tumor cells, which has been shown to rely on the expression
of cell surface calreticulin (Obeid et al., 2007). To address
these possibilities, we have first evaluated the frequency of
Tregs and MDSCs in the spleen of DTIC-treated tumor-bearing
mice and found that DTIC did not significantly alter the
frequency of these immunosuppressive cells (Figure 2a and b).
We then assessed whether DTIC promoted the maturation
of antigen-presenting cells by testing the effect of a single
systemic injection of DTIC or lipopolysaccharide on the
maturation pattern of splenic DCs. Although lipopolysac-
charide induced a massive upregulation of CD86 and CD40,
DTIC administration did not affect the expression of these
markers, ruling out DTIC involvement in DC maturation
(Figure 2c).
We next tested the ability of DTIC to trigger an
immunogenic form of cell death by monitoring the expres-
sion of cell surface calreticulin on B16 cells. Unlike
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Figure 1. Dacarbazine (DTIC) exerts an antitumor effect in a CD8-, IFN-c-,
and natural killer (NK)–dependent manner. (a) Wild-type (WT) (left panel) or
nude (right panel) mice were injected with 5105 B16F10 cells and treated
7 days after injection with one intraperitoneal (IP) injection of DTIC
(100mg kg1). Day 0: day of treatment (10 mice per group). (b–e) Mice were
injected with 5 105 B16F10 cells and treated 7 days after injection with one
IP injection of DTIC (100mg kg1). Mice received IP injection of (b) anti-CD8,
(c) CD4, (d) IFNg), (e) and anti-NK1.1 on day 5 after tumor cell injection and
then twice a week (10 mice per group). (f) Same as a with injection of 5 104
B16F10 cells. The experiments were performed three times, yielding similar
results. *Po0.05. NS, nonsignificant; PBS, phosphate-buffered saline.
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Figure 2. Dacarbazine (DTIC) activates natural killer (NK) and CD8þ T cells, but does not induce immunogenic cell death or have an impact on suppressive
cells. (a) Effect of DTIC on regulatory T cells (Tregs) (CD4þ FoxP3þ ). Mice bearing B16F10 tumors received either phosphate-buffered saline (PBS) or DTIC. The
panel shows the percentage of splenic Treg 5 days after drug administration. The experiments were performed three times, yielding similar results. (b) Effect
of DTIC on myeloid-derived suppressor cells (MDSCs) (Gr1þ CD11bþ ). Mice bearing B16F10 tumors either received PBS or DTIC. The panel shows the
percentage of splenic MDSCs 5 days after drug administration. The experiments were performed three times, yielding similar results. (c) Effect of DTIC on splenic
dendritic cell (DC) maturation. Tumor-free mice received an injection of PBS, lipopolysaccharide (LPS), or DTIC. Twenty-four hours after treatment, splenic
CD11chi DCs were examined by flow cytometry for CD86 (left) or CD40 (right) expression. The experiments were performed twice, yielding similar results.
(d) Effect of PBS, DTIC, and doxorubicin (Doxo) on calreticulin translocation. B16F10 tumor cells were cultured for 24 hours in complete medium alone (PBS) or
supplemented with DTIC or Doxo as a positive control. Calreticulin expression on the cell surface was determined by flow cytometry, and MFI was standardized
to the isotype control fluorescence. The experiments were performed twice. (e) Effect of DTIC on NK, CD8, and CD4 T-cell activation. Mice bearing B16F10
tumors either received no treatment (PBS) or one intraperitoneal administration of DTIC. Tumor-draining lymph nodes were harvested 2 days post treatment, and
the proportion of CD69-positive NK cells, CD8þ T cells, and CD4þ T cells was determined by flow cytometry. Right panel shows representative FACS
histograms for CD8þ T and NK cells. (f) Same as e with NKG2D staining. The mean fluorescence intensity was normalized to isotype-matched cells. The
experiments were performed twice, yielding similar results. *Po0.05. MFI, mean fluorescence index.
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doxorubicin, which is known to trigger calreticulin cell
surface expression (Obeid et al., 2007), DTIC treatment could
not trigger calreticulin membrane expression on B16 cells
(Figure 2d), suggesting that the antitumor effects of DTIC
cannot be explained by its ability to trigger an immunogenic
form of tumor cell death.
Finally, we found that DTIC injection did not modify the
number of total CD4, CD8, CD19, CD11c, or NK cells in
lymphoid organs of tumor-bearing mice (not shown). Never-
theless, we noted NK and CD8þ T-cell activation assessed by
CD69 (Figure 2e) and NKG2D (Figure 2f) labeling in tumor-
draining lymph nodes after DTIC injection. In vitro, DTIC did
not affect NK or CD8 T-cell phenotype (not shown).
Altogether, these data suggest that although the antitumor
effect of DTIC is dependent on CD8þ T and NK cells, DTIC
did not affect Tregs, MDSC, and DC maturation, and failed to
induce immunogenic death of tumor cells. In contrast, DTIC
induced local activation of NK and CD8þ T cells, suggesting
that the DTIC-mediated NK and CD8þ T-cell activation is
indirect.
DTIC induces the expression of NKG2D ligands and induces NK
cell activation
Previous reports have shown that chemotherapy-induced cell
stress triggers the expression of NKG2D ligands on leukemic
cell lines, leading to NK cell activation (Fine et al., 2010;
Nice et al., 2010). As our results showed NK cell activation
following DTIC treatment in vivo, we tested whether DTIC
induced NKG2D ligand expression in melanoma cells. We
found that DTIC induced Rae1 and Mult1 gene expression in
B16 cells (Figure 3a). This increased NKG2D ligand expres-
sion resulted in detection of membrane Rae-1 and Mult-1
proteins, as well as total NKG2D ligands, on B16F10 tumor
cells 24 hours following DTIC treatment (Figure 3b), whereas,
according to the literature, we failed to detect any of them in
phosphate-buffered saline (PBS)–treated B16F10 (Zhang and
Sentman, 2011). Thereafter, we tested NK cell cytotoxicity
against B16 cells after DTIC treatment. We observed that
DTIC enhances NK cell toxicity (Figure 3c). In addition, we
could demonstrate that coculture of NK cells with B16 cells
treated with DTIC induced a production of IFNg (Figure 3d).
We further observed that the lysis of DTIC-treated B16 cells
by NK cells was dependent on perforin/granzyme B but
not TRAIL, as shown by the use of concanamycin A or
blocking anti-TRAIL antibody (Figure 3e). Importantly, by
using a blocking NKG2D-Fc, we could observe that NKG2D
engagement was mandatory for both NK cell cytotoxic effects
(Figure 3f) and IFNg secretion (Figure 3g) when using DTIC-
treated B16 cells. Finally, we tested the dependency of DTIC
treatment efficacy in vivo. We treated melanoma-bearing
mice with DTIC along with isotype or depleting anti-NKG2D.
We observed that NKG2D blockade hinders the DTIC effect
on tumor growth (Figure 3h).
To generalize our in vitro and animal results, we took
advantage of a human melanoma cell line MelC (Fregni et al.,
2011). To check whether DTIC treatment induces upregula-
tion of NKG2D ligands in MelC cells, we analyzed transcripts
for MICA, MICB, ULBP1, ULPB2, and ULPB3 in MelC cells
treated or not treated with DTIC (Figure 4a). MICA and
MICB were significantly upregulated upon DTIC exposure,
whereas the other NKG2D ligands showed a slight increase
in expression. In accordance with these results, we also
detected the presence of MICA and MICB proteins in MelC
cells by flow cytometry (Figure 4b). To test the functional
relevance of this observation, we performed coculture of
human NK cells with PBS- or DTIC-treated MelC cells. DTIC
treatment efficiently sensitizes the melanoma target to NK
cell lysis, indicating the validity of our hypothesis in human
settings (Figure 4c). We also noted that this increase in target
mortality was prevented by a blocking anti-human NKG2D
antibody (Figure 4d). We confirmed this observation in other
human melanoma cell lines. We found that three out of
five tested melanoma cell lines are prone to NKG2D ligand
upregulation-dependent NK lysis induced by DTIC (data not
shown).
Altogether, these data demonstrate that DTIC-induced
NKG2D ligand upregulation on tumor cells leads to NK cell
activation.
DTIC-driven production of IFNc by NK cells triggers
upregulation of MHC-I and favors tumor cell killing by CTL
B16 cells poorly express MHC-I molecules at steady state,
and this phenomenon impedes their recognition by CD8þ T
cells (Zoller et al., 1988; Lugade et al., 2008). We observed
that the supernatant of NK cells cocultured with DTIC-treated
B16 cells induced the expression of MHC-I molecules on
fresh B16 cells. This MHC-I upregulation was entirely due to
IFNg, as IFNg blockade aborted the phenomenon (Figure 5a).
By using B16 cells expressing ovalbumin (OVA) antigen
(B16OVA), we showed that, although PBS-treated B16OVA
express low levels of MHC-I as expected (Lugade et al.,
2008), the supernatant of NK cells cocultured with DTIC-
treated tumor cells induced the expression of OVA peptide
(SIINFEKL)–MHC-I complex on tumor cell surface in an IFNg-
dependent manner, indicating enhanced endogenous tumor
antigen presentation (Figure 5b). We hypothesized that this
increased availability of peptide/MHC-I complexes may
enhance B16OVA susceptibility to antigen-specific cytotoxic
T cells. We took advantage of OT-I transgenic mice, in which
CD8þ T cells bear an OVA-specific TCR. In vitro, pretreat-
ment of B16OVA cells with the supernatant of NK cells
cocultured with DTIC-treated tumor cells enhances their
killing by OT-I CD8þ T cells (Figure 5c).
To test the in vivo relevance of this observation, we treated
mice bearing B16OVA tumors with DTIC, and then injected
them with carboxyfluorescein succinimidyl ester (CFSE)–la-
beled OT-I cells and monitored their outcome. We found that
DTIC treatment induced higher OT-I proliferation in tumor-
draining lymph nodes compared with control. This effect
is blunted by IFNg neutralization or NK cell depletion,
suggesting that DTIC-driven OT-I in vivo activation was
dependent on NK cell activation (Figure 5d).
Altogether, these data indicate that, in vivo and in vitro,
IFNg produced by NK cells after DTIC treatment enhances
tumor cell capacity to present tumor antigens on MHC-I and
favors CD8þ T-cell activation.
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CTLA4 blockade þ DTIC synergy relies on NK cells
Given that our previous experiments indicate the NK cell
dependency of the DTIC treatment, we questioned whether
NK cells are mandatory for efficacy of DTIC-based combined
chemotherapeutic regimen. Recently, treatment inhibiting
CTLA4, an inhibitor of T cell–based cytotoxicity (Walker and
Sansom, 2011), has proven beneficial in combination with
DTIC (Robert et al., 2011). We decided to test CTLA4þDTIC
inhibition in our experimental model, with or without NK
depletion. As expected from the literature (van Elsas et al.,
1999; Dranoff, 2011), the effect of anti-CTLA4 treatment
alone on tumor growth is comparable to that of DTIC alone,
and the anti-CTLA4þDTIC combination gives better anti-
tumor efficacy (Figure 6a). As already seen in Figure 1, DTIC
efficacy is totally blunted in mice depleted of NK cells;
furthermore, NK cell depletion abrogated not only the
antitumor effect of anti-CTLA4 alone but also that of anti-
CTLA4þDTIC (Figure 6b). These data support the rationale
that the in vivo antitumor effect of the combination of DTIC
þ anti-CTLA4 relies on NK cell action.
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Figure 3. Dacarbazine (DTIC) induces expression of NKG2D ligands and natural killer (NK cell) activation. (a) Messenger RNA (mRNA) expression of NKG2D
ligands in B16F10 cells before and after treatment with 24 hours DTIC (0.4 g l1). Relative expression normalized to b-actin level. The experiments were
performed five times with similar results. (b) FACS expression of membranous Rae1 (left panel), Mult-1 (middle panel), and total NKG2D ligand (right panel)
before and after treatment with 24 hours DTIC. The mean fluorescence intensity was normalized to isotype-matched cells. The experiments were performed
three times, yielding similar results. (c) B16F10 cells treated or not treated with DTIC were incubated with the indicated number of NK cells. Cell death was
assessed using 40,60-diamidino-2-phenylindole staining by flow cytometry after 48 hours. The experiments were performed twice, yielding similar results.
(d) B16F10 cells treated or not treated with DTIC were incubated with NK cells at 25/1 E/T ratio. IFNg production after 24 hours was determined by ELISA. The
experiments were performed twice, yielding similar results. (e) Untreated B16F10 cells (upper panel) and B16F10 treated for 24 hours with 0.4 g l1 DTIC (lower
panel) were incubated with the indicated number of NK cells in the presence of phosphate-buffered saline (PBS), concanamycin A (ConA), or anti-TRAIL mAb.
Cell viability was assessed using the crystal violet test after 48 hours. The experiments were performed twice. (f, g) B16F10 cells treated with DTIC were
incubated with NK cells at 25/1 E/T ratio in the presence of NKG2D-Fc molecule or control Fc protein. (f) Cell viability was assessed using the crystal violet test.
(g) IFNg production after 24 hours was determined by ELISA. (h) Same as Figure 1, with injection of isotype (lower panel) or blocking anti-mouse NKG2D (upper
panel). The experiments were performed twice. *Po0.05. NS, nonsignificant.
www.jidonline.org 503
A Hervieu et al.
Dacarbazine and Anticancer Immune Responses
DISCUSSION
This paper reports the immunological properties of DTIC in
the context of growing melanoma. We unraveled the
capacity of DTIC to trigger NKG2D ligand expression on
both murine and human tumor cells, resulting in augmented
NK cell cytotoxic properties and IFNg production. This
cytokine production is involved in the enhancement of MHC-
I presentation of tumor-associated antigen and better CTL
activity. In our in vivo model, the effect of DTIC on the
immune system seems predominant, as its effect on tumor
growth is lost in T cell–deficient nude mice, or in mice
depleted of CD8þ T cells, NK cells, or IFNg. Thus, DTIC can
be added to the expanding list of chemotherapeutic agents
whose antitumor effect depends, at least in part, on their
capability to enhance the anticancer immune response
(Zitvogel et al., 2008).
Much evidence demonstrates that mouse and human
NKG2D ligands are often expressed poorly on normal cells,
but their expression levels are upregulated on tumor cells or
virus-infected cells (Mistry and O’Callaghan, 2007). NKG2D
ligands are also expressed by melanoma cell lines and tumors
(Casado et al., 2009; Paschen et al., 2009). A given tumor cell
line or primary tumor typically expresses one or more
NKG2D ligands, although not usually all of them, suggesting
a complexity in their regulation. Radiation (Kim et al., 2006;
Gannage et al., 2008) and DNA-damaging agents (Fine et al.,
2010) have demonstrated their capacity to upregulate
NKG2D ligand expression. This regulation is mediated by
the major DNA damage checkpoint pathway initiated by
ATM (ataxia telangiectasia, mutated) or ATR (ATM- and
Rad3-related) protein kinases (Soriani et al., 2009). In this
vein, we here report that DTIC is able to enhance expression
of NKG2D ligand by mouse (Figure 3) and human (Figure 4)
melanoma cell lines, favoring NK-driven killing and NK-
derived IFNg production. To our knowledge, this fact is
previously unreported. The expression of NKG2D ligands in
cells that do not express them endogenously renders the cells
more prone to NK cell–mediated lysis in vitro, and reduces
the tumorigenicity of tumor cell lines in vivo (Cerwenka
et al., 2000, 2001; Diefenbach et al., 2000, 2001). Further
research is, however, warranted to unravel the molecular
mechanisms accounting for the enhanced NKG2D ligand
expression on tumor cells following DTIC treatment.
The fact that DTIC treatment was ineffective in nude mice
seems surprising, as DTIC is widely used as a cytotoxic drug
for the treatment of melanoma. We propose that the NKG2D
ligand modulation by the DTIC treatment may be sufficient to
trigger an antitumor immune response, which strengthens this
therapeutic effect. In previous studies, we also demonstrated
that anthracyclines, oxaliplatine, and 5-fluorouracil antitu-
mor effect was also dependent on an immune response
(Apetoh et al., 2007; Ghiringhelli et al., 2009; Vincent et al.,
2010). It is conceivable that, in melanoma patients, NKG2D
ligand upregulation triggers activation of immune effectors
and enhances the efficacy of the treatment. Therefore, it
could be relevant to check the NKG2D ligand expression in
tumor cells before and after chemotherapy and perform a
correlation analysis between NKG2D ligand expression and
response to chemotherapy to corroborate this hypothesis.
DTIC effect was totally abrogated in NK- and IFNg-
depleted mice, yet featured an early and transient effect
in CD8þ T cell–depleted mice (Figure 1c), suggesting a
sequential activation of these immune effectors following
DTIC treatment. We propose that IFNg secretion establishes a
key link between the activation of innate and adaptive
immune effectors. Indeed, enhanced MHC-I expression by
IFNg leads to higher accessibility of endogenous tumor antigens,
processed and presented through peptide/MHC complexes
on tumor cells, explaining the consequent vulnerability of
melanoma cells to CTL. Furthermore, by augmenting the
availability of antigens, DTIC enables the survival of low-
avidity TCR clonotypes, easing epitode spreading (Palermo
et al., 2010), thereby favoring increased anticancer immunity
and reduced tumor progression.
Specific stimulation of the host’s immune system to induce
melanoma tumor rejection has been attempted. Approaches
to tumor-specific immunotherapy of melanoma have in-
cluded chemoimmunotherapy combining IFN-a or IL-2 with
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DTIC therapy, the use of tumor lysates and whole tumor
vaccines, tumor-derived peptides, DC-based vaccination
protocols, and adoptive transfer of tumor-specific T cells
(Kadison and Morton, 2003). These approaches have so far
obtained little success in the clinic, are complex and labor-
intensive, thereby limiting their potential for widespread use.
However, the implementation of a new immunotherapy was
recently approved by Food and Drug Administration for the
treatment of unresectable or metastatic melanoma. Targeting
immunosuppression by the anti-CTLA-4 antibody ipilimumab
revealed a clinical benefit after failure of first-line chemother-
apy (Hodi et al., 2010). Recently, a new chemoimmunother-
apy protocol with the association of ipilimumab and DTIC
demonstrated superiority in terms of overall survival com-
pared with DTIC administered alone (Robert et al., 2011).
However, it should be pointed out that the clinical advantage
is only observed in a small percentage of patients and should
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therefore be balanced with the expansive cost of ipilimumab
(about 100,800 dollar to treat one patient (Kaplan, 2011)).
Therefore, increasing our knowledge on the immune-
mediated effects of chemotherapy is an important step to
optimize any immune-based regimen in melanoma. In this
regard, our results showing that the combination of DTIC
with anti-CTLA4 relies on NK cells hint us about the potential
clinical relevance of our observation. Indeed, it is concei-
vable that some tumors may resist the DTIC-induced NKG2D
ligand upregulation, and in these patients the immune effects
of DTIC would be reduced or absent. Our results also point
that CTLA4 blockade might be effective against tumor growth
only in the presence of NK cells, which seems surprising and
needs further investigations, according to the fact that CTLA4
inhibition is thought to only act through dampening of
T-cell inhibition (Robert and Ghiringhelli, 2009; Tarhini and
Iqbal, 2010).
To conclude, our results indicate that DTIC antitumor
efficacy relies on NKG2D ligand expression by tumor cells,
which results in NK cell activation and IFNg secretion,
leading to increased tumor MHC-I presentation and higher
CTL efficacy. We speculate that patients who feature
upregulation of NKG2D ligands on tumor cells and NK cell
activation after one cycle of DTIC may be better responders
to immunomodulation and may be candidates in clinical
trials that assess the efficacy of T cell–activating agents such
as ipilimumab. As such, NKG2D ligand expression might be
a predictive biomarker for DTIC treatment response; how-
ever, these data must first be validated in a clinical trial.
MATERIALS AND METHODS
Mice and cell lines
B16F10 melanoma cells, syngeneic of C57BL/6, were obtained from
the ATCC (Molsheim, France). B16F10 cells expressing OVA (B16OVA)
were a kind gift from Laurence Zitvogel. MelC human melanoma
cell line was a kind gift from Anne Caignard. Cells were cultured in
RPMI 1640 (Lonza, Levallois Perret, France) with 10% fetal bovine
serum enriched with 0.4mM sodium pyruvate, 4mM (4-(2-hydro-
xyethyl)-1-piperazineethanesulfonic acid), penicillin, streptomycin,
and amphotericin B. C57BL/6 and Nude mice were purchased from
the Centre d’e´levage Janvier (Le Genest St Isle, France); OT-I were
from Charles River (Saint Germain sur l’Arbresle, France) and were
used at 6–10 weeks of age. Animals were all maintained according to
the Animal Experimental Ethics Committee Guidelines.
Tumor model
B16F10 cells (5 105 in 100 ml PBS) were subcutaneously injected
into the flank of mice. Mice were treated 7 days after tumor injection
and received a unique intraperitoneal injection of DTIC at
100mg kg1 body weight.
Reagents
We used DTIC (De´tice`ne; Sanofi Aventis, Paris, France) and
doxorubicin (Pfizer, Paris, France). NKG2D Fc was from R&D
Systems (Minneapolis, MN). Anti-TRAIL antibody (clone N2B2) was
a kind gift from Laurence Zitvogel. The DAPI (40,60-diamidino-2-
phenylindole), CFSE, concanamycine A, crystal violet, and lipopo-
lysaccharide were bought from Sigma-Aldrich (Saint-Quentin
Fallavier, France). ELISA assay for IFNg was from BD Pharmingen
(Le Pont de Claix, France). To investigate the role of IFNg in the
induction of MHC-I expression, a blocking anti-IFNg antibody
(XMG1.2, BioXCell, West Lebanon, NH) was added to the culture
medium at 10 mgml1. All magnetic separations were performed
with Miltenyi Biotec SAS (Paris, France) reagents, according to the
manufacturer’s protocol. For the in vivo depletion or blocking
experiments, we used intraperitoneal injections of 150mg of anti-
NK1.1 (clone PK136), anti-IFNg (clone XMG1.2), anti-CD4 (GK1.5),
anti-CD8 (53-6.72), anti-NKG2D (HMG2D), or anti-CTLA4 (9H10),
all from BioXCell, twice a week. IL-2 was from Chiron (Suresne,
France).
Flow cytometry
Antibodies anti-Rae1 (CX1), anti-MHC-I H2Kb (AF6-88.5), anti-
CD11c (HL3), anti-Gr1 (RB6-8/5), anti-CD3 (145-2C11), anti-CD4
(L3T4), and anti-CD49b (DX5) were purchased from BD PharMin-
gen; anti-CD40 (1C10), anti-CD86 (PO3.1), anti-Foxp3 (236A/E7),
anti-MHC -II (M5/114.15.2), anti-CD11b (M1/70), anti-H-2Kb/
SIINFEKL (25-D1.16), and anti-Mult-1 (5D10) were from eBioscience
(Paris, France); and anti-human NKG2D (1D11) and anti-mouse
CD69 (H1.2F3) were from Biolegend (San Diego, CA). Anti-mouse
RAE-1(186107), anti-MICA(159227), and anti-MICB(236511) were
from R&D system. Anti-human IgG was from Beckman Coulter
(Roissy, France). All DAPI-positive events were excluded as
dead cells. The data were produced using a LSRII cytometer (BD
Pharmingen) equipped with FACSDiva (BD Pharmingen) and
analyzed with FlowJo (Tristar, Ashland, OR).
Detection of calreticulin expression on tumor cells
B16F10 cancer cells were cultured for 24 hours in complete culture
medium supplemented or not supplemented with DTIC (0.4. g l1),
doxorubicin (25 mM), or PBS. Cells were fixed with 1% paraformal-
dehyde, and then saturated with 200 ml of PBS supplemented with
30% fetal bovine serum before being stained with a rabbit anti-
calreticulin antibody (AbCam, Paris, France) for 20minutes at 4 1C,
followed by Cy5-conjugated anti-rabbit antibody (Amersham, GE
Healthcare, Velizy-Villacoublay, France).
Quantitative PCR
Total RNA was extracted using TRIZOL (Invitrogen, Villebon sur
Yvette, France) as recommended by the manufacturer. The RNAs
were rehydrated and measured with a NanoDrop 1000 (Thermo-
Scientific, Illkirch, France). Reverse transcription was performed
using the kit ‘‘M-MLV Reverse Transcriptase’’ (Invitrogen) as recom-
mended by the manufacturer. The samples were then placed in a
Biometra (Archamps, France) thermocycler. The quantitative PCR
reaction was performed using the kit ‘‘SYBR Green PCR Master Mix’’
(Applied Biosystems, Villebon sur Yvette, France) according to
the manufacturer’s recommendations, on an Applied 7500 device
(Applied Biosystems). Relative messenger RNA levels were deter-
mined using the DCt method. Values were expressed relative to
Actb. The sequences of the oligonucleotides used in this study are
listed in the Table 1.
NK cell cytotoxic assay
B16F10 were cultured for 24 hours in complete culture medium
supplemented or not supplemented with DTIC at 0.4 g l1. After
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24 hours, B16F10 cells were harvested and incubated with increas-
ing numbers of NK cells and IL-2 (1,000UIml1). In some wells,
NKG2D Fc was added at a concentration of 10 mgml1. After
48 hours, cells were collected and B16F10 death was assessed using
4’-6-Diamidino-2-phenylindole staining by flow cytometry. NK cells
were excluded as CD49b-positive events.
For human experiments, peripheral blood mononuclear cells
were isolated from healthy volunteers’ blood, and NK cells were
separated using the NK cell isolation kit (Miltenyi). NK cells were
incubated overnight with melanoma target MelC, previously treated
with PBS or DTIC. In some wells, antihuman NKG2D (BD
biosciences) was added at a concentration of 10 mgml1. Tumor
cells were harvested and death was assayed using DAPI staining by
flow cytometry or CellTiter assay (Promega, Lyon, France).
Determination of CD8þ T-cell activation and cytotoxicity
For in vitro experiments, B16OVA cells were cultured for 24 hours in
complete culture medium supplemented or not supplemented with
the supernatant of NK cells cocultured with DTIC-treated B16F10
cells. B16OVA cells were then harvested and incubated for 48 hours
with increasing ratio of CD8þ T OT-I cells. Cell viability was
assessed using the crystal violet test.
For in vivo experiments, B16OVA cells (5 105 cells or 5 104)
were subcutaneously injected into the thigh of C57BL/6 mice.
Mice were treated or not treated with DTIC 7 days after injection.
CD8þ T cells from OT-I mice spleen and lymph nodes were isolated
by magnetic selection, labeled by CFSE (10 mmol l1), and then
injected intravenously 8 days after tumor implantation. Some mice
were treated with depleting anti-NK1.1 or anti-IFNg antibodies. Five
days after injection of OT-I cells, mice were killed and tumor-
draining inguinal lymph node was removed. OT-I cell activation was
assessed by CFSE dilution by flow cytometry.
Statistical analysis
Tests used were Student’s t-test or Mann–Whitney test for the
comparison of parametric and nonparametric means. For compar-
ison of more than two groups, analysis of variance with Bonferroni
post-test was used. All tests were performed with the GraphPad
Prism software (La Jolla, CA). All P-values were two-tailed. A P-value
of o0.05 was considered statistically significant for all experiments
and is indicated with *.
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